Refining pharmacogenetic research in schizophrenia: Control for patient-related variables

中國醫藥大學機構典藏 China Medical University Repository, Taiwan > 台中附設醫院 > 期刊論文 > Item 310903500/30314

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.cmu.edu.tw/ir/handle/310903500/30314

题名:	Refining pharmacogenetic research in schizophrenia: Control for patient-related variables
作者:	Lane, HY;Chang, YC;Huang, CL;Chang, WH
贡献者:	附設醫院精神醫學部;Tzu Chi Univ, Dept Psychol, Hualien 970, Taiwan;Dalin Tzu Chi Gen Hosp, Dept Psychiat, Hualien 970, Taiwan;Tamkang Univ, Dept Math, Taipei, Taiwan;China Med Univ & Hosp, Dept Psychiat, Taichung, Taiwan
日期:	2003
上传时间:	2010-09-24 14:53:03 (UTC+8)
出版者:	WILEY-LISS
摘要:	There is strong evidence to suggest that genetic variation plays an important role in interindividual differences in medication response and toxicity. Most of the previous pharmacogenetic studies, however, cannot be reconfirmed. Of note, drug efficacy or side effects depend not only on genetic factors but also on nongenetic factors, such as illness duration, past treatment history, and drug dosage or blood concentration. However, most pharmacogeneticists did not consider or control the possible impact of the nongenetic factors. Schizophrenia is a severe neuropsychiatric disorder with a polygenic mode of inheritance that is also governed by nongenetic factors. Schizophrenia's symptoms are principally subdivided into two subtypes, positive and negative. The positive symptoms include delusions and hallucinations; the negative symptoms, blunted affect and social withdrawal. Atypical antipsychotics are usually superior in the treatment of negative symptoms than typical agents. Although atypical agents are becoming the mainstay for schizophrenia treatment, what makes an antipsychotic "atypical" remains unclear. One of our recent studies have simultaneously evaluated the effects of genetic and nongenetic determinants on the efficacy of risperidone (a widely used atypical antipsychotic agent). We found that 5-HT2A receptor 102-T/C polymorphism could predict clinical response (mainly for negative symptoms rather than positive symptoms) in schizophrenia. Among nongenetic factors, fewer previous hospitalizations and higher risperidone dosage also predicted better treatment response after control for the 102-T/C polymorphism and other confounders. It is hoped that this novel study model could revolutionize future research in pharmacogenetics or other fields of genetics. (C) 2003 Wiley-Liss, Inc.
關聯:	DRUG DEVELOPMENT RESEARCH 60(2):164-171
显示于类别:	[台中附設醫院] 期刊論文

文件中的档案:

没有与此文件相关的档案.

在CMUR中所有的数据项都受到原著作权保护.

TAIR相关文章

数据加载中.....